2022
Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study
Van Name MA, Kanapka LG, DiMeglio LA, Miller KM, Albanese-O’Neill A, Commissariat P, Corathers SD, Harrington KR, Hilliard ME, Anderson BJ, Kelley JC, Laffel LM, MacLeish SA, Nathan BM, Tamborlane WV, Wadwa RP, Willi SM, Williams KM, Wintergerst KA, Woerner S, Wong JC, DeSalvo DJ. Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. Journal Of Diabetes Science And Technology 2022, 17: 976-987. PMID: 35343269, PMCID: PMC10348002, DOI: 10.1177/19322968221084667.Peer-Reviewed Original ResearchConceptsFamily behavioral interventionsContinuous glucose monitoringBlood glucose monitoringCGM useYoung childrenGlucose monitoringOne-year resultsType 1 diabetesContinuous glucose monitor useHemoglobin A1cCGM groupGlycemic outcomesType 1Behavioral interventionsExtension phaseBGM groupMonitor useOne-year studyCGM technologyDiabetes technologyGlycemiaHypoglycemiaChildrenBehavioural supportGroup
2015
Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry. Diabetes Care 2015, 38: 971-978. PMID: 25998289, DOI: 10.2337/dc15-0078.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesT1D Exchange Clinic RegistryContinuous glucose monitoringDiabetic ketoacidosisSevere hypoglycemiaClinic registryMetabolic controlOutcome of treatmentOptimal metabolic controlRegistry findingsAdvanced diabetes technologiesAverage HbA1cMean hemoglobinYounger patientsCommon complicationCurrent treatmentNew therapiesAge 30HbA1cType 1DiabetesGlucose monitoringDiabetes technologyAge